SEC Form 4 · accession 0001209191-18-007618
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Altshuler
Officer — EVP, Global Research and CSO
Period of report
Feb 2, 2018
Accepted (ET)
Feb 5, 2018 · 5:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 2, 2018 | M | 1,796 | $91.05 | A | 51,557 | D | |
| Common StockF2,F3 | Feb 2, 2018 | S | 600 | $165.24 | D | 50,957 | D | |
| Common StockF3,F4 | Feb 2, 2018 | S | 996 | $166.12 | D | 49,961 | D | |
| Common Stock | Feb 2, 2018 | S | 100 | $167.81 | D | 49,861 | D | |
| Common Stock | Feb 2, 2018 | S | 100 | $169.49 | D | 49,761 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $91.05 | Feb 2, 2018 | M | 1,796 | D | — | Feb 1, 2026 | Common Stock | 1,796 | 14,368 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $165.24 (range $164.80 to $165.71).
- F3Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $166.12 (range $165.81 to $166.43).
- F5The option vests in 16 quarterly installments from 2/2/2016.